Ultrasound, Physical Examination, and CA 125 Measurement for the Detection of Recurrence after Conservative Surgery for Early Borderline Ovarian Tumors

Zanetta, Gerardo; Rota, S.; Lissoni, Andrea Alberto; A, Meni; Brancatelli, G.; Buda, Alessandro

doi:10.1006/gyno.2000.6099

Cited by 88 publications

(67 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gotlieb et al, studying patients with BOT, showed that increased concentrations of CA 125 can indicate relapse, although increases did not occur in all patients with relapse (16). Zanetta et al described increases in CA 125 above the cut-off in only 17% of patients at the time of relapse (25). This finding is in agreement with our data, as we also observed that not all patients with recurrent disease showed an increase in CA 125.…”

Section: Discussionsupporting

confidence: 93%

Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors

Lenhard

Nehring

Nagel

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Background: The aim of this study was to assess the prognostic value of cancer antigen (CA) 125 and CA 72-4 in patients with ovarian borderline tumor (BOT). Methods: All women diagnosed and treated for BOT at our institution between 1981 and 2008 were included into this retrospective study (ns101). Preoperatively collected serum samples were analyzed for CA 125 (Architect, Abbott and Elecsys, Roche) and CA 72-4 (Elecsys, Roche) with reference to clinical data and compared to healthy women (ns109) and ovarian cancer patients (ns130). Results: With a median of 34.7 U/mL (range 18.1-385.0 U/mL) for CA 125 and 2.3 U/mL (range 0.2-277.0 U/mL) for CA 72-4, serum tumor markers in BOT patients were significantly elevated as compared to healthy women with a median CA 125 of 13.5 U/mL (range 4.0-49.7 U/mL) and median CA 72-4 of 0.8 U/mL (range 0.2-20.6 U/mL). In addition, there was a significant difference compared with ovarian cancer patients who showed a median CA 125 of 401.5 U/mL (range 12.5-35,813 U/mL), but no difference was observed for CA 72-4 (median 3.9 U/mL, range 0.3-10,068 U/mL). Patients with a pT1a tumor stage had significantly lower values of CA 125 but not of CA 72-4 compared with individuals with higher tumor stages (median CA 125 29.9 U/mL for pT1a vs. 50.9 U/mL for )pT1a; ps0.014). There was a trend for increased concentrations of CA 125 but not of CA 72-4 in the presence of ascites, endometriosis or peritoneal implants at primary diagnosis. With respect to the prognostic value of CA 125 or CA 72-4, CA 125

show abstract

Section: Discussionsupporting

confidence: 93%

Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors

Lenhard

Nehring

Nagel

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…The results are in agreement with other studies [5][6][7][8] in both early ovarian cancer and borderline tumors [9]. There has always been a demand for less radical surgery and fertility sparing surgery if the treatment is reasonably safe.…”

Section: Discussionsupporting

confidence: 91%

Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer

Borgfeldt

Iosif

Måsbäck

2007

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Results: During the follow-up period of median 92 months, range 11-185 months, no relapse was found in the patients with stage Ia tumors including both the borderline tumors (n=12) and the invasive well (n=9) and moderately (n=1) differentiated ovarian cancers. One patient with poorly differentiated ovarian cancer stage 1c was pregnant at 13 weeks at the primary operation.Although, unilateral oophorectomy was performed she insisted in continuing the pregnancy. At 37 weeks she had a caesarian section and the ovarian cancer was disseminated. Chemotherapy was given but she died less than a year later. No other patient received chemotherapy. In total 30 children was born by 15 patients. Prophylactic removal of the remaining ovary +/-hysterectomy was accepted only in six of the women after completing their desire to have more children. However, several of these patients do not accept the recommendation of prophylactic oophorectomy of the contra lateral ovary and hysterectomy after completion of childbearing age. Conclusions4

show abstract

“…Elevated serum tumor markers such as CA125, CEA and CA19-9 have been reported in only 25% to 60% of women with BOT (18,(23)(24)(25).…”

Section: Accepted As a Distinct Histological Entity By The Internatiomentioning

confidence: 99%

Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: Multivariate analysis of a French multicentre study

Poncelet

Fauvet

Yazbeck

et al. 2010

European Journal of Surgical Oncology

View full text Add to dashboard Cite

To cite this version:C. Poncelet, R. Fauvet, C. Yazbeck, C. Coutant, E. Darai. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: Multivariate analysis of a french multicentre study. EJSO -European Journal of Surgical Oncology, WB Saunders, 2010, 36 (11) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 1 IMPACT OF SERUM TUMOR MARKER DETERMINATION ON THE MANAGEMENT OF WOMEN WITH BORDERLINE OVARIAN TUMORS: MULTIVARIATE ANALYSIS OF A FRENCH MULTICENTRE STUDY.C PONCELET 1-2 , R FAUVET 1 , C YAZBECK 3 , C COUTANT 1 , and E DARAI 1 *. Condensation:Preoperative evaluation of serum tumor markers impacts on the management of borderline ovarian tumors.3 Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.C PONCELET, R FAUVET, C YAZBECK, C COUTANT, and E DARAI. ABSTRACT:Objective: To evaluate the contribution of preoperative serum tumor markers to manage borderline ovarian tumors (BOT).Study Design: Retrospective multicentre study including 317 BOT. Serum tumor marker levels of CA125, CA19-9, CEA, and CA15-3 were determined by radio-immunoassay. Conclusion: Serum tumor marker assays modified both preoperative assessment and surgical management of BOT. Results

show abstract

Ultrasound, Physical Examination, and CA 125 Measurement for the Detection of Recurrence after Conservative Surgery for Early Borderline Ovarian Tumors

Cited by 88 publications

References 12 publications

Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors

Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors

Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer

Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: Multivariate analysis of a French multicentre study

Contact Info

Product

Resources

About